HEALTH PROFESSIONAL · SOURCE READING

Immunotherapy

Source: Laryngeal Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: May 14, 2025 · Captured 2026-09-09.

Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary.

Context: Treatment of Metastatic and Recurrent Laryngeal Cancer / Treatment Options for Metastatic and Recurrent Laryngeal Cancer

Immunotherapy (inhibitor of the programmed death-ligand 1 [PD-L1] pathway) can be used after platinum-based failure in patients with metastatic or locally recurrent disease.[9,10]

Source links and citations

Continue within this section

Pembrolizumab →Nivolumab →

Publication references

Read the original reference and check its publication notices.

PubMed 27718784 · Original source
PubMed 30509740 · Original source

Preserved source evidence · Not medical advice